Honduras
Tuberculosis profile
| High HIV burden |
Population  2013 8.1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.23 (<0.01–0.87) 2.9 (0.06–11)
Mortality (HIV+TB only) 0.11 (0.072–0.15) 1.3 (0.89–1.9)
Prevalence  (includes HIV+TB) 6 (3–10) 74 (37–125)
Incidence  (includes HIV+TB) 4.4 (3.4–5.6) 54 (42–69)
Incidence (HIV+TB only) 0.45 (0.34–0.57) 5.6 (4.3–7)
Case detection, all forms (%) 68 (54–89)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.8–3.4) 12 (5.8–22)
MDR-TB cases among notified pulmonary
TB cases
43 (19–82) 27 (13–48)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 941   187
Pulmonary, clinically diagnosed 460   29
Extrapulmonary 356   8
       
Total new and relapse 2 981    
Previously treated, excluding relapses      
Total cases notified 2 981    
Among 2 981 new and relapse cases:
162 (5%) cases aged under 15 years; male:female ratio: 1.4
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 133 (7%) 152 (68%) 366
Laboratory-confirmed RR-/MDR-TB cases     6
Patients started on MDR-TB treatment     4
TB/HIV 2013 Number (%)
TB patients with known HIV status 2 564 (86)
HIV-positive TB patients 263 (10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 181 (69)
HIV-positive TB patients on antiretroviral therapy (ART) 242 (92)
HIV-positive people screened for TB 654  
HIV-positive people provided with IPT 168  
Treatment success rate (%)
New and relapse cases registered in 2012 89
Previously treated cases, excluding relapse, registered in 2012 17
HIV-positive TB cases, all types, registered in 2012 63
RR-/MDR-TB cases started on second-line treatment in 2011 43
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.2
Culture (per 5 million population) 3.2
Drug susceptibility testing (per 5 million population) 0.6
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 13
% Funded domestically 16%
% Funded internationally 14%
% Unfunded 69%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-09-04 Data: www.who.int/tb/data